By Ben Hirschler

LONDON (Reuters) - U.S. biotech company Human Genome Sciences Inc, fighting a hostile bid from GlaxoSmithKline Plc, set a July 16 deadline for definitive takeover offers on Friday and made another plea for GSK to join the auction process.